News

Four new studies reveal details about how B cells in the immune system churn out antibodies that become increasingly potent and specific after we’re vaccinated or exposed to an infection.

In a first-of-its-kind clinical trial, researchers found that intravenous therapies made from virus-specific T-cells (VST) can effectively treat immunocompromised pediatric patients, far surpassing the current standard of care.

Recently approved Alzheimer's drugs work by tagging amyloid plaques for clearance by the brain's microglia. Washington University School of Medicine in St. Louis researchers are developing an alternative approach, using a homemade antibody to directly mobilize microglia.

Last month a story about a 62-year-old male made headlines after he claimed to have received 217 vaccines against SARS-CoV-2. Scientists invited the individual for tests to investigate what happens in the body of a hypervaccinated individual.

A mouse model has helped scientists uncover the biological mechanisms behind the autoimmune condition dermatomyositis.

In a new study, researchers have found that a protein called FOXO1 improves the survival and function of CAR T cells, which may lead to more effective CAR T cell therapies and could potentially expand its use in difficult-to-treat cancers.

The molecular mechanisms behind the action of the hepatitis B and D virus inhibitor bulevirtide have been revealed, potentially paving the way to more targeted treatments.

Language models can be used to home in on partial genome sequences and optimize those sequences to study biology and improve medicine, and have designed more effective mRNA vaccines.

New Phase 1 data from Memorial Sloan Kettering Cancer Center shows an investigational cancer vaccine may elicit lasting immune response in patients with pancreatic cancer.

An oral vaccine against recurrent UTIs could reduce the need for antibiotic treatment.